Oral acyclovir induced hypokalemia and acute tubular necrosis a case report

Jonathan S. Chávez-Iñiguez¹,2*, Ramón Medina-Gonzalez¹, Lilia Aguilar-Parra³, Eduardo J. Torres-Vázquez¹,2, Pablo Maggiani-Aguilera¹,2, Enrique Cervantes-Pérez¹,2 and Guillermo García-García¹,2

Abstract

Background: Acyclovir is one of the most common prescribed antiviral drugs. Acyclovir nephrotoxicity occurs in approximately 12–48% of cases. It can present in clinical practice as acute kidney injury (AKI), crystal-induced nephropathy, acute tubulointerstitial nephritis, and rarely, as tubular dysfunction. Electrolytes abnormalities like hypokalemia, were previously described only when given intravenously.

Case presentation: A 54 year-old female presented with weakness and lower extremities paresis, nausea and vomiting after receiving oral acyclovir. Physical examination disclosed a decrease in the patellar osteotendinous reflexes (++ / ++++). Laboratory data showed a serum creatinine level of 2.1 mg/dL; serum potassium 2.1 mmol/L. Kidney biopsy was obtained; histological findings were consistent with acute tubular necrosis and acute tubulointerstitial nephritis. The patient was advised to stop the medications and to start with oral and intravenous potassium supplement, symptoms improved and continued until serum potassium levels were > 3.5 meq/L.

Conclusions: The case reported in this vignette is unique since it is the first one to describe hypokalemia associated to acute tubular necrosis induced by oral acyclovir.

Keywords: AKI, Acyclovir, Hypokalemia
Case presentation
Clinical history and laboratory data
A 54 year-old female presented to the outpatient clinic with weakness and lower extremities paresis, nausea and three times vomiting, after receiving clindamycin, dicloxaciline, and oral acyclovir 400 mg each 8 h were prescribed to treat a dental abscess. Relevant past medical history included allergy to penicillin and smoking for 20 years. Physical examination disclosed good hydration status, decrease in the patellar osteotendinous reflexes (++ / ++++). Initial laboratory data showed a serum creatinine level of 2.1 mg/dL; blood urea nitrogen 86.4 mg/dL; serum potassium 2.1 mmol/L, sodium 134 mmol/L, phosphorus 1.7 mg/dL, and magnesium 2.15 mg/dL. (Table 1).

Additional investigations
The patient was advised to stop the medications and to start with oral potassium supplement. She noticed improvement of the weakness; however, due to persistent hypokalemia, the patient was admitted to the hospital for further evaluation; new blood test showed a serum creatinine level of 1.7 mg/dL and blood urea nitrogen 76.3 mg/dL; serum potassium 2.5 mmol/L, sodium 139 mmol/L, phosphorus 2 mg/dL, and magnesium 1.88 mg/dL; urine sediment was unremarkable; 24 h

Table 1 Laboratory data
| Parameters               | Baseline | Day 3  | Day 11 | Day 13 | Day 14 | Day 15 | Reference range |
|-------------------------|----------|--------|--------|--------|--------|--------|-----------------|
| Hemoglobin (g/dL)       | 13.3     | 12.8   | 12.5   | 10.82  | 11.1   | -      | 12.0–16.0       |
| Hematocrit, %           | 35.4     | 33.8   | 36.7   | 31.8   | 32.45  | -      | 37–47          |
| Platelets, K/mcl         | 326,000  | 318,000 | 253,700 | 207,100 | 203,600 | -      | 150,000 - 500,000 |
| White blood cells (K/mcl)| 6290     | 5790   | 4780   | 3860   | 4120   | -      | 3600–11,600    |
| Glucose (mg/dL)         | 136      | 123    | 100    | 159    | 139    | -      | 60–99          |
| Urea (mg/dL)            | 86.4     | 76.3   | 63.8   | 45.8   | 42     | -      | 166–48.5       |
| Creatinine (mg/dL)      | 2.1      | 1.7    | 1.18   | 1.1    | 1.14   | -      | 0.5–1.2        |
| Uric acid (mg/dL)       | 8.1      | 7.3    | 5.4    | 4.8    | 5      | -      | 2.4–5.7        |
| Potassium (mmol/L)      | 2.1      | 2.5    | 3      | 2.8    | 2.8    | 3.1    | 3.5–5.1        |
| Sodium (mmol/L)         | 134      | 139    | 140    | 141    | 139    | 139    | 135–145        |
| Calcium (mmol/L)        | 10.1     | 9.7    | 9.3    | 8.5    | 8.5    | 8.9    | 8.6–10         |
| Chloride (mmol/L)       | 89       | 95     | 106    | 108    | 109    | 102    | 98–107         |
| Phosphorus (mg/dL)      | 1.7      | 2      | 2.9    | 3      | 3.4    | 2.2    | 2.5–4.5        |
| Magnesium (mg/dL)       | 2.15     | 1.88   | -      | -      | -      | -      | 1.6–2.6        |
| Albumin (g/dL)          | 4.9      | 4.8    | 4.1    | 3.3    | 3.5    | -      | 3.5–5.2        |
| Blood pH                | -        | 7.45   | -      | -      | -      | -      | 7.35–7.45      |
| CO₂ mmHg                | -        | 37.2   | -      | -      | -      | -      | 35–45          |
| HCO₃ (mmol/L)           | -        | 25.3   | -      | -      | -      | -      | 23–25          |
| Urine pH (pH dipstick)  | 7        | 7      | 6.5    | -      | -      | -      | 5.0–8.0        |
| Dipstick protein, mg/dL | negative | negative | negative | -      | -      | -      | Negative       |
| Red blood cells (dipstick) | negative | negative | negative | -      | -      | -      | Negative       |
| leucocyte esterase (dipstick) | negative | negative | 15     | -      | -      | -      | Negative       |
| Urinary casts           | none     | none   | None   | -      | -      | -      | None           |
| Urine protein (g/day)   | -        | -      | -      | 0.23   | -      | -      | -              |
| Urine potassium (mmol/day) | -     | 49    | -      | 86     | -      | -      | < 30           |
| Urine sodium (mmol/day) | -        | 86     | -      | 162    | -      | -      | -              |
| Urine calcium (mmol/day) | -       | 89    | -      | 57     | -      | -      | -              |
| Urine phosphorus (mg/day) | -     | -     | -      | 143    | -      | -      | -              |
| Spot urine potassium (mEq/L) | -  | 20.1  | -      | 30     | -      | -      | < 15           |
| Spot urine sodium (mEq/L) | -    | 37    | -      | 57     | -      | -      | < 20           |
| Spot urine calcium (mEq/L) | -    | -    | -      | 1.73   | -      | -      | -              |
| Spot urine phosphorus (mEq/L) | -  | -    | -      | 4.6    | -      | -      | -              |
urine potassium was 49 mEq/day, sodium 86 mEq/day, and calcium 89 mg/day. A renal ultrasound showed a normal-size kidney, without hydronephrosis. Kidney biopsy was performed.

**Kidney biopsy**

Two fragments of kidney tissue were obtained (Fig. 1). By stereoscopic evaluation 11 glomeruli were identified. By light microscopy 9 glomeruli were observed; three were globally sclerosed and the remaining glomeruli were normal. Tubular atrophy was seen in 15–20% of the tubules; the remaining tubules showed vacuolated, granular cytoplasm, focal sloughing of the epithelium, and regenerative changes of the brush edge of tubular cells and hyaline casts (Fig. 1a). By Masson’s trichrome stain (Fig. 1b and c), the interstitium exhibited 0–15% fibrosis, with inflammatory infiltrate by lymphocytes, plasma cells, and few eosinophils, that penetrated the tubular epithelium. Arterioles and medium-caliber arteries were permeable without vasculitis or thrombi. By Jones (Fig. 1d) tubule-interstitial nephritis infiltrated with abundant inflammatory cells were observed. Immunofluorescence (Fig. 1e) was negative for IgM, IgG, IgA, C3c, C1q, kappa, lambda, fibrinogen, and albumin. Histological findings were consistent with acute tubular necrosis and acute tubulointerstitial nephritis.

**Clinical follow-up**

Due to persistent hypokalemia oral and intravenous potassium replacement was started with good tolerability and no adverse events, symptoms improved; the patient was discharged 4 days later with a serum potassium of 3.1 mEq/L; oral replacement of potassium was continued until serum potassium levels were > 3.5 meq/L, after few days later she restart her normal life.
Diagnosis
Hypokalemia and acute kidney injury due to oral acyclovir.

Discussion and Conclusions
Ramírez et al. have described acyclovir and other drug-induce causes of hypokalemia. Drug-induced severe potassium disturbances were found in 32.3% of the cases, and in 23% were lethal; hypokalemia was present in 23.4% of life-threatening potassium disturbances [7].

Intravenous acyclovir is the most common therapy against herpes virus; it can induce crystalluria and lead to AKI. In a population-based study, hypokalemia developed in 46% of patients receiving iv acyclovir compared to 21% in the control group; individuals with a previous normal potassium levels, altered estimated glomerular filtration rate, or previous use of diuretics were at higher risk of developing hypokalemia [13]. They suggested that iv acyclovir induces hypokalemia by reduced renal plasma flow and/or by crystal-induced distal tubular damage.

Other possible mechanisms include tubular dysfunction mediated by aldheyde metabolite of acyclovir; this complication could explain the urinary loss of potassium and others electrolytes (Fig. 2a); by direct injury to the renal tubular epithelia causing tubular cell degeneration and sloughing. Indeed, renal biopsy findings of patients with acyclovir toxicity include bulging of tubular cells, dilated tubular lumens, loss of proximal-distal tubular differentiation, flattening and vacuolization of epithelial cells, and epithelial cells mitoses [5] (Fig. 2b); and crystalluria, which usually develops 24–48 h after the initiation of acyclovir therapy due to its low solubility in urine. Severe intraparenchymal crystal precipitation can cause interstitial congestion and hemorrhage, leading to a decrease of renal blood flow (Fig. 2c) [14].

Acyclovir does not seem to affect the tubular handling of creatinine, suggesting that the pronounced, transient

![Fig. 2](image-url) Effects of acyclovir on the renal parenchyma. a Tubular dysfunction and electrolyte loss; b Direct injury to the renal tubular cell, necrosis and tubular obstruction; c Crystalluria and crystals in the tubular parenchyma
elevation in plasma creatinine, may be due solely to decreased glomerular filtration rate (GFR) as a result of renal dysfunction [5].

To prevent the possible the adverse effects of acyclovir; it has been recommended to establish euvoelemia, slow intravenous infusion (over 1–2 h), adjusting the dose according to renal function, and to avoid the use of concomitant nephrotoxic agents prior to acyclovir administration [4].

It is important to mention that a great limitation of the presentation of our case is that we cannot adjuge causality for the intake of acyclovir, but there is biological and clinical plausibility that sustains this event. Strength of our case is that we have obtained renal tissue for histological analysis, since it is not common to perform a kidney biopsy in the presence of acute kidney injury secondary to drugs.

The detection, reporting, and prevention of ADRs due to acyclovir, are essential to provide appropriate, safe, and effective therapy with this drug.

Acyclovir nephrotoxicity occurs in approximately 12–48% of cases, is associated with 3 patterns of kidney injury: tubular dysfunction and electrolyte loss, direct injury to the renal tubular cells and crystalluria, in 46% of patient that receive IV acyclovir develop hypokalemia. Probably both IV and oral acyclovir are associated with hypokalemia. To prevent the possible the adverse effects of acyclovir, establish euvoelemia, slow intravenous infusion, adjusting the dose to renal function, avoid concomitant nephrotoxic agents. Early detection of renal and tubular dysfunction of ADRs due to acyclovir, are essential to provide appropriate, safe, and effective therapy with this drug.

**Abbreviations**
ADRs: Adverse drug reactions; AKI: Acute kidney injury; CA-AKI: Community-acquired acute kidney injury; GFR: Glomerular filtration rate; IV: Intravenous

**Acknowledgements**
none.

**Funding**
We don't have any funding.

**Availability of data and materials**
We have all the clinical and histological data.

**Authors’ contributions**
JSCI, RMG, GGG contribute in conception, design, acquisition of data, analysis and interpretation of data, been involved in drafting the manuscript, given final approval of the version to be published. JSCI was responsible for creating the images. LGAP, EJTV, PMA and ECP contribute in acquisition of data, analysis and interpretation of data, been involved in drafting the manuscript, given final approval of the version to be published. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**
not applicable.

**Consent for publication**
Written informed consent was obtained from the patient for publication of this Case Report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.